A case of synchronous bilateral lung cancers: EML4-ALK positive adenocarcinoma in the right lung and adenocarcinoma in situ (the former bronchioloalveolar carcinoma) in the left lung

BMC Pulmonary Medicine

Seiichi Hirota¹  Kazuhiro Teramura²  Kayo Ueda²  Masahide Kaji⁴  Shinjiro Mizuguchi⁴  Kengo Takeuchi³  Ikuo Matsuda¹ 

[1] Department of Surgical Pathology, Hyogo College of Medicine, Hyogo 663-8501, Japan;Department of Pathology, Yodogawa Christian Hospital, Osaka 533-0032, Japan;Pathology Project for Molecular Targets, the Cancer Institute, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan;Department of Surgery, Yodogawa Christian Hospital, Osaka 533-0032, Japan

关键词: Adenocarcinoma in situ;    Lung adenocarcinoma;    EML4-ALK;   

Others  :  1109917
DOI  :  10.1186/1471-2466-13-25

 received in 2012-11-28, accepted in 2013-04-19,  发布年份 2013

【 摘 要 】

Background

Recently it has been revealed that lung adenocarcinomas with distinct gene mutations or fusions are associated with particular histopathological entities. For example, epidermal growth factor receptor (EGFR) gene mutations are often associated with well differentiated adenocarcinoma of the lung with bronchioloalveolar pattern. On the other hand, echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene in a subset of lung adenocarcinoma is related to mucinous cribriform histology.

Case presentation

Reported herein is a case of synchronous EML4-ALK positive lung adenocarcinoma and adenocarcinoma in situ in the bilateral lungs of a 55-year-old Japanese woman. The woman had EML4-ALK positive lung adenocarcinoma in the right lower lung while adenocarcinoma in situ in the left upper lung, which was EML4-ALK negative.

Conclusion

To our knowledge, this is the first report of synchronous, bilateral lung adenocarcinomas composed of EML4-ALK positive and negative ones.

【 授权许可】

   
2013 Matsuda et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Travis WD, Brambilla E, Muller-Hermelink HK, Haris CC, World Health Organization: Classification of Tumours. Pathology & Genetics: tumours of the lung, pleura, thymus, and heart. Lyon: IARC Press; 2004.
• [2]Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE: International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
• [3]Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
• [4]Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
• [5]Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008, 3:13-17.
• [6]Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K: EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009, 22:508-515.
• [7]Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H: RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012, 18:378-381.
• [8]Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y: KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012, 18:375-377.
• [9]Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, Kim YT, Kim JI, Kang JH, Seo JS: A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012, 22:436-445.
• [10]Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
• [11]Nakata M, Sawada S, Yamashita M, Saeki H, Kurita A, Takashima S, Tanemoto K: Surgical treatments for multiple primary adenocarcinoma of the lung. Ann Thorac Surg 2004, 78:1194-1199.
• [12]Graziano P, Cardillo G, Mancuso A, Paone G, Gasbarra R, De Marinis F, Leone A: Long-term disease-free survival of a patient with synchronous bilateral lung adenocarcinoma displaying different EGFR and C-MYC molecular characteristics. Chest 2011, 140:1354-1356.
• [13]Dohmoto K, Fujita J, Ohtsuki Y, Kotsuna N, Mitsunaka H, Kuwabara H, Takahara J: Synchronous four primary lung adenocarcinoma associated with multiple atypical adenomatous hyperplasia. Lung Cancer 2000, 27:125-130.
• [14]Suzuki K, Takahashi K, Yoshida J, Nishimura M, Yokose T, Nishiwaki Y, Nagai K: Synchronous double primary lung carcinomas associated with multiple atypical adenomatous hyperplasia. Lung Cancer 1998, 19:131-139.
• [15]Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:1103-1109.
• [16]Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T: EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005, 29:633-639.
• [17]Yoshimoto K, Yoshida J, Ishii G, Nishimura M, Hishida T, Nagai K: Two lung adenocarcinomas in the same lobe: multiple primaries or intrapulmonary metastasis? Ann Thorac Cardiovasc Surg 2011, 17:584-587.
• [18]Mitsudomi T, Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007, 98:1817-1824.
• [19]Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, Asaka R, Nakajima T, Mano H, Takeuchi K: KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012, 7:e31323.